Testing venetoclax, lenalidomide, and rituximab for new mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests a combination of venetoclax, lenalidomide, and rituximab in people newly diagnosed with mantle cell lymphoma. It aims to control the lymphoma and see how safe and effective this approach is for newly treated patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have been newly diagnosed with mantle cell lymphoma confirmed by a tissue biopsy (histology).
- Your overall daily functioning is good (ECOG score 0–2, meaning you’re not very limited).
- You must be able to take pills by mouth (swallow tablets/capsules).
- You must enroll in the lenalidomide (Revlimid) REMS program and be willing to follow its rules, including pregnancy testing and birth control if relevant.
- You likely cannot have had chemotherapy for mantle cell lymphoma before (no prior MCL chemotherapy).
- You should not have serious recent neurologic or heart problems (including stroke or brain bleeding in the last 6 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs, nemtabrutinib (a targeted pill) and rituximab (an antibody infusion), for people with mantle cell lymphoma (MCL) who haven't had prior treatment. The goal is to see how well these drugs work together to control the lymphoma.
This Phase 2 trial tests how well the combination of pirtobrutinib and venetoclax works for people with mantle cell lymphoma that has come back or did not respond to treatment. It’s meant to help shrink the lymphoma and improve outcomes after prior therapies.
This trial is testing a combination of chemotherapy and targeted drugs for people who have just been diagnosed with mantle cell lymphoma and haven't had any prior treatment (except short-term steroids or local radiation). It aims to see if adding newer targeted therapies can help keep the lymphoma in remission.
This study tests a new combination treatment for mantle cell lymphoma that has returned or not responded to standard therapies. The goal is to see if the combination helps control the cancer.
This study tests a combination of a targeted pill (zanubrutinib) with standard chemotherapy (R-CHOP/R-DHAP) for people newly diagnosed with mantle cell lymphoma. The goal is to see how well this approach works and to potentially improve treatment outcomes for this type of lymphoma.
This trial tests a new combination of medications for mantle cell lymphoma that has returned or not responded to other treatments. The goal is to see if this combination can shrink tumors and is safe for patients like you.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.